Definitely taking the quiet conservative approach. Fair enough I...

Definitely taking the quiet conservative approach. Fair enough I guess. Whilst I can't figure a good reason not to say something along the lines of "we met with the FDA and had an informative and productive discussion" it would likely only invite a barrage of speculation and questioning. I trust in their judgement to wait for all the information and make useful informed announcements rather than attempt to influence short term SP movements that would only have a minor, transient effect anyway. Also I'm not sure how the Market will respond to an announcement concerning the meeting. It's no doubt great if the FDA are onboard with Neuren's plan to simplify trial requirements to reduce the burden on patients but it may also be viewed as supporting the go it alone narrative. I'm in the camp with those who believe Neuren can only behave as if they're progressing themselves until a decent offer is put forward. Other things could move the SP up near term though like improving Daybue sales, positive animal models on new indications and PRV sale at a high price. Excited to be a holder despite the current SP.